FLT3 and acute myeloid leukemia: Similarly, combined whole-exome sequencing (WES) with scRNA-seq in longitudinal analysis of t(8;21) AML and FLT3-ITD AML revealed substantial heterogeneity both within and between blast cells of each patient and more heterogeneity among diagnosis-relapsed pairs (39).